Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Improving Physician Assessment and Treatment Outcomes: When a Physician is the Patient (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This workshop will help physicians and other healthcare providers to better understand their profession’s unique risk factors for adverse outcomes such as substance abuse, suicide and burnout. Additionally, it will help providers who are in the position of evaluating and/or treating a colleague or fellow healthcare provider to obtain better outcomes and to provide optimal diagnostics and treatment.

    Physician burnout and suicide rates are at their highest levels and steadily climbing. Workload, electronic medical records, decreased time with patients and poor work-life balance have all be proposed as possible contributors to the epidemic of physician burnout. In contrast, physicians have the same rates of mental illness (such as depression and anxiety) and substance abuse as the general population. However, the substance physicians tend to abuse are alcohol and prescription medications (v.s. illicit substances for the general pop). With all of these factors colliding into "Physician Health," it is no surprise that physician well-being committees are commonly tasked with assessing a "troubled physician". Burnout and suicide are not limited to seasoned members of the field of medicine. Medical students and residents have burnout levels as high as 50%. We are just now starting to uncover the epidemic of medical student and resident suicide rates. An intensive diagnostic evaluation of a physician is a repetitively new concept. Prior to the 1990's Physicians were confronted and in many cases forced into treatment. Currently, the practice is to encourage a physician suspected of having a substance abuse, mental health or behavioral problem into a minimum 72 hour diagnostic evaluation to uncover whether or not they need treatment. Physicians face similar barriers to treatment as the general population such as shame. However, they also face barriers such as fear of losing their careers, losing medical malpractice coverage, losing credentialing/hospital privileges and more if they are diagnosed with mental illness or substance abuse. Therefore, the delivery and quality of a diagnostic evaluation for a physician are critical. Our workshop will cover the current healthcare environment and the epidemiological and other risk factors that physicians face. We will discuss the process of intervention and what to do when a colleague, staff member or resident/medical student is suspected of being impaired. Finally, in great detail we will cover the process of evaluating and treating a physician from a multi-disciplinary approach. Evaluation and care for a physician includes a multi-disciplinary team, including addiction medicine, addiction psychiatry, forensic/addiction psychology and beyond. We will provide an interactive experience for the audience to help them incorporate a better understand of both physician health and a thorough diagnostic evaluation into their practice or into the medical institution.

    Matthew Goldenberg

    DO

    Matthew Goldenberg D.O. is an expert in the evaluation and treatment of mental health disorders and is an addiction specialist in Santa Monica, CA. He is double Board Certified in Psychiatry and Addiction Psychiatry. Dr. Goldenberg is the Associate Medical Director of Professional Health Services at Promises Treatment Centers. Dr. Goldenberg specializes in helping professionals (many of whom are healthcare providers) obtain and learn to maintain long-term recovery from drugs, alcohol and/or mental illness. In this capacity, Dr. Goldenberg assists in multi-disciplinary evaluations to help uncover if there is an underlying addiction or mental health condition and also provides treatment which includes individual medication and non-medication treatment options and group therapy facilitation. Dr. Goldenberg continues to engage in research and medical education as a member of the Medical Staff and as an Assistant Professor of Psychiatry at Cedars Sinai Medical Center, in Los Angeles, California. Dr. Goldenberg also maintains a small private practice in Santa Monica, CA. This affords the ability to provide highly individualized and evidence-based treatment to a select group of motivated patients.  Dr. Goldenberg completed an Addiction Psychiatry Fellowship through UCLA and Psychiatry Residency at Banner University Medical Center, of the University of Arizona, in Phoenix, Arizona. Dr. Goldenberg completed medical school at Midwestern University, Arizona College of Osteopathic Medicine. Dr. Goldenberg matriculated at Santa Clara University for his undergraduate education. 

    Karen Miotto

    MD

    Dr. Karen Miotto is a Clinical Professor in the Department of Psychiatry and Behavioral Sciences at UCLA, the Director of the UCLA Addiction Medicine Service, and Chair of the UCLA Medical Staff Health Program. Dr. Miotto is the Chair of California Public Protection & Physician Health (CPPPH) and is the Chair of the Committee on Wellbeing of Physicians of the California Society of Addiction Medicine (CSAM). She is dedicated to promoting physician wellness and educating others on how to reduce physician distress, burnout, substance misuse and mental illness in the medical profession. Additionally, Dr. Miotto is frequently an invited speaker at local and international addiction medicine meetings. She is the recipient of a career development award from the National Institute on Drug Abuse and is an investigator in the area of addiction pharmacology.

    Greg Skipper

    MD, DFASAM

    Dr. Skipper is a Distinguished Fellow of the American Society of Addiction Medicine and a certified Medical Review Officer. He is currently the director of Professional Health Services at Promises Professionals Treatment Program in Santa Monica CA. This treatment program is a separate Promises program that focuses on evaluation and treatment of professionals. Dr. Skipper has conducted over 2,000 in-depth evaluations on licensed professionals over the past 30 years. Dr. Skipper previously served as Medical Director of the Alabama Physician Health Program (1999-2011) and was on the council that created and oversaw the Oregon Health Professionals Program (1989-1993). Dr. Skipper was also the primary innovator of ethylglucuronide, EtG, testing, a superior drug test for detecting abstience from alcohol use, in the United States and abroad and is an expert in alcohol biomarkers and other drug testing. He was a principle investigator of The Blueprint Study, the most extensive National Study of Physician Health Programs, funded by a Robert Wood Johnson Foundation grant, and is the author of more than 100 articles and book chapters regarding drug testing, physician health and contingency monitoring. Dr. Skipper was formerly Medical Director of Springbrook Hazelden and he was a chief advisor to the designing of the professionals program at Betty Ford Center and Bradford Health Services. Dr. Skipper assisted in developing Physician Health Programs in Melbourne Australia and Salzburg Austria. Dr. Skipper is also Medical Director of an educational company, Professional Boundaries, Inc., that conducts over 80 courses per year nationally in major cities regarding Professional Boundaries, Medical Ethics, Apprpriate Prescribing and Medical Records. 

  • The Rational Understanding and Use of Urine Drug Testing in Addiction Medicine (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This workshop presentation will tackle the controversies related to urine drug testing and explore possibilities for best practices in various practice settings. Laboratory and testing technologies will be described with a look at the sensitivity and specificity of the testing type as well as considerations of cost to the patient and cost (staff time, supplies) to the provider in these various settings.

    The utilization of testing for substances that can identify relapse or continued use has become a common part of the practice of Addiction Medicine. As testing has become more ubiquitous there have been introduced a multitude of products and strategies that provide information to the practicing physician. Good practice decisions benefit greatly from accurate, appropriate information. Strategies for obtaining that information can rely on point of care (POC) testing or testing in a licensed laboratory. Laboratory testing can be either presumptive or definitive, or both based on an agreed paradigm. However, products have over-represented inherent sensitivity and specificity, commercial labs have misguided physicians as to costs, and errors of interpretation have had devastating impact on the lives of patients. This presentation will describe the most common products and strategies, including cost data and turnaround time and describe practice protocols to address most common presentations and practices, with consideration of cost effectiveness and accuracy. Current research and laboratory processes will be reviewed and applicability to various practice settings will be explored.

    Howard Wetsman

    MD, DFASAM

    Howard C. Wetsman, M.D., is the Chief Medical Officer and a founder of Townsend Addiction Treatment Centers. He is responsible for overseeing all aspects of the treatment of addiction within Townsend's several outpatient clinics and inpatient treatment facility. Dr Wetsman is board certified in Psychiatry and ABAM certified in Addiction Medicine. He is a clinical assistant professor at Louisiana State University Medical School, a member of the Louisiana Board of Examiners in Dietetics and Nutrition and a member of the Louisiana Governor's Drug Policy Board. He is a member of numerous professional societies including the ASAM and the AMA. He is a Distinguished Fellow of ASAM and was recently elected to the Board as regional director of Region VII. He is the author of two books, Questions and Answers on Addiction, and, Healing Stories. Dr. Wetsman maintains a frequent blog at addictiondoctor.org that covers a wide range of issues related to the disease of addiction and is active on twitter @addictiondocMD.

    A. Kenison Roy III

    MD, DFAPA, FASAM

    Ken Roy, MD is president and medical director of Biobehavioral Medicine Company, LLC in Metairie, LA., an addiction focused medical practice, and Addiction Recovery Resources, Inc., an outpatient and residential treatment program for addiction, also in Metairie. Dr Roy is founder and medical director of the Dual Diagnosis Unit (DDU) at River Oaks Hospital in Harahan, LA and also has had a successful addiction and psychiatric private practice for over 25 years. Dr. Roy received his medical degree from Tulane University School of Medicine in New Orleans. He completed his internship at the Charity Hospital of New Orleans and a residency in psychiatry at the Tulane University School of Medicine. Dr. Roy is a Distinguished Fellow of the American Psychiatric Association, a Fellow of the American Society of Addiction Medicine and is certified by the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. He is a member of the American Academy of Addiction Psychiatry and the American Medical Association and the Louisiana Psychiatric Medical Association (LPMA) and is a Past President of LPMA. He has held leadership positions in the American Society of Addiction Medicine (ASAM) and is currently an At Large member of the Board of Directors.

  • Off-Label Pharmacological Approaches to AUD - What's Hot and What's Not? (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This workshop will survey off-label approaches to treating alcohol use disorder, such as antidepressants, antipsychotics, anticonvulsants and anti-anxiety agents. Attendees will identify patients likely to benefit, or not benefit, from an off-label treatment strategy. The rationale for off-label treatment strategies range from treating overt symptoms to returning brain stress systems to within a homeostatic range of functioning following withdrawal. The clinical research literature that supports or does not support various pharmacological treatment strategies will be presented. Discussion is encouraged.

    This workshop will survey off-label approaches to treating alcohol use disorder, such as antidepressants, antipsychotics, anticonvulsants and anti-anxiety agents. Attendees will identify patients likely to benefit, or not benefit, from an off-label treatment strategy. The rationale for off-label treatment strategies range from treating overt symptoms to returning brain stress systems to within a homeostatic range of functioning following withdrawal. The clinical research literature that supports or does not support various pharmacological treatment strategies will be presented. Discussion is encouraged.

    Barbara Mason

    PhD

    Barbara J. Mason, Ph.D. is the Pearson Family Professor, Director of the Pearson Center for Alcoholism and Addiction Research, Director of the Laboratory of Clinical Psychopharmacology, and Acting Chair of the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute, La Jolla, CA. Dr. Mason's work in medication development for the treatment of alcohol use disorders has been recognized with a MERIT Award from the National Institutes of Health (NIH), the Dean's Senior Clinical Research Award from the University of Miami School of Medicine, and the Andrew W. Mellon Foundation Teacher-Scientist Award from Cornell University Medical College. Dr. Mason conducted the seminal studies identifying nalmefene as having therapeutic potential for alcohol dependence; nalmefene (Selincro) has recently received regulatory approval for the treatment of alcohol dependence in the European Union. Dr. Mason also served as overall Principal Investigator for the US multicenter trial of acamprosate (Campral) for the treatment of alcohol dependence which was conducted in support of FDA approval. Dr. Mason has served on the National Advisory Councils of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Advisory Council of the National Institute on Drug Abuse (NIDA). Dr. Mason is an elected Fellow of the American College of Neuropsychopharmacology and has held multiple editorial positions, including serving as a current member of the editorial board for the Journal of Addiction Medicine. Dr. Mason holds the Pearson Family Chair, an endowed position in alcohol and addiction research at The Scripps Research Institute, and is currently conducting a program of NIH-funded research that includes human laboratory studies to screen medications for therapeutic potential for alcohol dependence and clinical trials to evaluate the safety and efficacy of novel medications for alcohol and cannabis dependence.

  • The ASAM Pain & Addiction: Common Threads Course XVIII 2017 (7.5 CME)

    Product not yet rated Contains 5 Product(s)

    Participants will have the opportunity to learn about the new research and clinical guidelines on treating patients with pain and addiction and how to apply these to improve patient outcomes.

    The theme for the 18th year of The ASAM Pain & Addiction: Common Threads Course is There and Back Again. In the past couple years, research and clinical guidelines for treating patients with pain and/or addiction have evolved dramatically, challenging the traditional way providers think about pain and addiction. Experts in the field will review the scientific, legislative, and clinical updates from the recent months and examine how these updates will affect the methods providers use to treat their patients. Presenters will also address how the “traditional” pain and addiction provider has changed and how to get providers from diverse backgrounds on the same page for patient care. Participants will learn about the many paradigm-shifting updates to the field through a series of mini-lectures. Participants will discuss ways to apply these changes to their practices with a rousing afternoon discussion with peers. Course attendees will leave the course with new knowledge and an understanding that can be immediately applied to their clinical practice.

    This course is aimed toward healthcare providers, at any level, who see patients with chronic pain and substance use disorders. Provider specialties can include, but are not limited to: addiction medicine, pain medicine, emergency medicine, internal medicine, anesthesiology, and psychiatry. 

    Upon completion, participants should be able to: 

    1. Identify and describe the new developments affecting the science, policy, and clinical practice of pain and addiction. 

    2. Analyze new research and science to develop practical applications for treatment or further research. 

    3. Evaluate their current practice, while considering new recommendations/best practices to recognize strengths or gaps. 

    4. Find and use apps, websites, or other resources to support their practice or their patient’s treatment. 

    5. Assess their feelings and attitudes towards the treatment of patients with pain and addiction. 

    Accreditation Council for Continuing Medical Education (ACCME)

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    The ASAM Pain & Addiction: Common Threads Course XVIII

    The American Society of Addiction Medicine designates this enduring material for a maximum of 7.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (Tmoc)

    This course has been approved by the American Board of Addiction Medicine (ABAM).  Physicians enrolled in the ABAM Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 7.5 AMA PRA Category 1 Credit(s)™ for completing the The ASAM Pain & Addiction: Common Threads Course XVIII.

    American Psychological Association (APA)

    The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    CME Committee Members

    • Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair
    • Catherine Friedman, MD, FASAM, Vice-Chair
    • Noel Ilogu, MD, MRCP, FASAM
    • Herbert L. Malinoff, MD, FACP, DFASAM
    • Edwin A. Salsitz, MD, DFASAM
    • John C. Tanner, DO, CCFC, DFASAM

    Staff - Sandy Metcalfe, Consultant, ASAM CME Committee, Professional Development Department

    CME Committee, Program Planning Committee and Faculty Disclosure Information

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Pain & Addiction Pre-Conference Course Faculty

    Name

    Disclosure

    Andrea Barthwell, MD, DFASAM

    Alere (not current); Apple Tree Life Sciences; Braeburn Pharmaceuticals (not current); Encounter Medical Group, P.C.; Ideal Option; The Manor (not current); Millennium Health (not current); Two Dreams; U.S. DOJ

    Marla Golden, DO, FACEP

    No Financial Relationships or Conflicts of Interest

    William F. Haning, III, MD, DFASAM, DFAPA

    No Financial Relationships or Conflicts of Interest

    William S. Jacobs, MD

    No Financial Relationships or Conflicts of Interest

    Andrew J. Kolodny, MD, FASAM

    No Financial Relationships or Conflicts of Interest

    Laura Morgan, PharmD

    No Financial Relationships or Conflicts of Interest

    Mark Pew

    No Financial Relationships or Conflicts of Interest

    Melvin I. Pohl, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    Ilene Robeck MD, FASAM

    No Financial Relationships or Conflicts of Interest

    Mark Seltzer, JD

    No Financial Relationships or Conflicts of Interest

    Michael P. Sprintz, DO, FASAM

    Cellarian Health, LLC Equity, CEO; Endo Pharmaceuticals, Honorarium, Chronic Pain Advisory Board Member

    Corey Waller, MD, MS, DFASAM

    No Financial Relationships or Conflicts of Interest

    Alexander Walley, MD, FASAM

    No Financial Relationships or Conflicts of Interest

    Mark Weiner, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

     

    ASAM Pain & Addiction Pre-Conference Course Planning Committee

     

    Name

    Disclosure

    Mark Weiner, MD, DFASAM (Chair)

    No Financial Relationships or Conflicts of Interest

    Corey Waller, MD, MS, DFASAM

    No Financial Relationships or Conflicts of Interest

    William S. Jacobs, MD

    No Financial Relationships or Conflicts of Interest

    Laura Morgan, PharmD

    No Financial Relationships or Conflicts of Interest

    Melvin I. Pohl, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    Ilene Robeck MD, FASAM

    No Financial Relationships or Conflicts of Interest

    Michael P. Sprintz, DO, FASAM

    Cellarian Health, LLC Equity, CEO; Endo Pharmaceuticals, Honorarium, Chronic Pain Advisory Board Member

    Name

    Disclosure

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    No Financial Relationships or Conflicts of Interest

    Catherine Friedman, MD

    No Financial Relationships or Conflicts of Interest

    Noel Ilogu, MD, MRCP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Herbert L. Malinoff, MD, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Edwin A. Salsitz, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/Speaker

  • Becoming Certified in Addiction Medicine through ABPM (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This session will review recent changes in the process of becoming board certified in addiction medicine.

    Starting in the fall of 2017, ABPM will offer physicians who are certified by a Member Board of the American Board of Medical Specialties (ABMS) the opportunity to become certified in the subspecialty of addiction medicine. The next five years following the date of the first exam is an optimum time for physicians to become Board Certified in addiction medicine. Physicians who are already certified by any of the 24 member Boards and have substantial experience in the field of addiction medicine are eligible to apply to take the examination. During the first five years the examination is given, individuals will NOT be required to complete an addiction medicine fellowship. After that, a one-year addiction medicine fellowship will be required. Upcoming Dates/Deadlines: 2017 Exam Applications Open: April 3 thru May 31, 2017. 2017 Exam Dates: October 16-28, 2017. For more info see ABPM booth in exhibit hall or www.theabpm.org.

    Marie A. Krousel-Wood

    MD, MSPH

    M.A. “Tonette” Krousel-Wood MD, MSPH, FACPM, FAHA is the Chair of the American Board of Preventive Medicine, Professor of Medicine in the Tulane School of Medicine, Professor of Epidemiology in the Tulane School of Public Health and Tropical Medicine, and serves in leadership roles including the Associate Provost for the Health Sciences at Tulane University.   

    She is actively engaged in NIH-funded clinical research and clinical trials focused on adherence to prescribed therapies, management of hypertension, health services and outcomes in patients with chronic cardiometabolic diseases.  In addition to her own research, she is committed to training the next generation of scientists and co-directs pre- and post-doctoral career development programs including serving as the Principal Investigator and Research Director for the NIH K12 Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) faculty career development award. She has presented her research findings at regional, national, and international meetings and has collectively published over 100 peer-reviewed articles, reports and book chapters. 
    She has held numerous leadership positions nationally including member and Chair of the National Institutes of Health Study Section, Health Services Organization and Delivery, President of the Southern Society for Clinical Investigation, President of Delta Omega national public health honorary society, member of the Board of Regents for the American College of Preventive Medicine, Chair and Director of the American Board of Preventive Medicine, and member of the National Institutes of Health Center for Scientific Review (NIH-CSR) Advisory Council. 

    Benson Munger

    PhD

    Benson Munger, PhD, is the Interim Executive Director of the American Board of Preventive Medicine.

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

  • Improving Care with Triage, Assessment, Contingency Management & Monitoring Technology (1.5 CME)

    Contains 3 Component(s), Includes Credits

    This session will discuss what the clinical and resource benefits of adopting new technological innovations are and how data for all three approaches are informing clinical and policy interventions.

    Academic-entrepreneurial partnerships have generated computer-assisted innovations in: 1) comprehensive assessment/placement, 2) triage, and 3) contingency management. Data suggest improved outcomes and adoption. 1) Comprehensive assessment with CONTINUUM TM, the standard implementation of ASAM's Criteria, is a computer-guided, structured interview that operationalizes medical necessity criteria. CONTINUUM's decision engine can automate utilization review (UR). Through CMS's 1115 federal waiver program, county/state Medicaids are preparing to adopt it. In Los Angeles county (population: 10.1 million), piloting began in July 2016. UCLA is evaluating feasibility and impact on intakes and patient engagement. The web application captures: duration of assessment, completion rates, recommended placements, reasons for discrepant placements, patient characteristics, and satisfaction. The data may determine whether and how to proceed with county-wide adoption; how to streamline Medicaid and commercial insurance UR; determination of what levels of care, numbers of beds/slots are needed; and quality improvement. 2) Triage with the first derivative product of CONTINUUM, CONTINUUM Triage TM, emerged at the request of LA County and is also used in Massachusetts. This 20-question, computer-guided, structured interview (10-15 minutes, telephonic or in-person) determines the provisional level of care in which to complete the patient's CONTINUUM comprehensive assessment. SUD outcomes are improved when patients are provided the right care, at the right time, in the right setting, for the right duration - the goals of CONTINUUM Triage. Massachusetts also piloted both CONTINUUM and Triage, also for the CMS 1115 Waiver. Funded by the Governor's Opioid Working Group, Triage is being piloted in walk-in Opioid Urgent Care Centers in three high overdose cities. Both pilots analyze how often Triage's provisional recommendations are correctly matched to the final LOC recommendations of CONTINUUM. 3) Contingency management (CM), a high efficacy evidence-based practice, has been limited in its adoption by implementation burdens. CM restores healthy brain reward function with immediate small incentives that grow along a progressive reinforcement schedule. CM rewards healthy behaviors (e.g., sobriety) across all addictive substances, in many populations. DynamiCare Health, a fully-automated, scalable, patent-pending technology alleviates provider burdens by (1) ethically managing CM incentives, (2) automatically tracking/reporting data, and (3) using machine learning to provide impending relapse/dropout alerts for proactive intervention. Programs enroll new patients via the web. It provides an easy-to-use escrow account into which the patient deposits funds for CM reward incentives (e.g., from wages, welfare, family allowance, crowdfunding donations). The patient downloads the DynamiCare smartphone app for appointment tracking (via GPS), random/smart drug testing, and reward notifications. DynamiCare ships "selfie"-validating breathalyzers, CO detectors, and/or saliva drug test cups to the patient. Abstinence, medication adherence, or treatment attendance rewards transfer from the escrow account onto a debit card. Initial back-testing on spending data with machine learning has generated new, previously un-hypothesized independent variables in drug addiction, correctly predicting 70% of acute drop-outs. These technology developments offer nationwide implementation of data-driven care, service provision, payment reform, and outcomes improvement. Data for all three approaches are informing clinical and policy interventions.

    David Gastfriend

    MD, DFASAM

    David R. Gastfriend, MD, served on the faculty of Harvard Medical School for 25 years, most recently as Director of the Addiction Research Program at Massachusetts General Hospital (MGH). His studies of the Patient Placement Criteria published by the American Society of Addiction Medicine (ASAM) have been supported by the NIH's National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the U.S. Centers for Disease Control, U.S. state governments, managed care corporations, including Aetna Behavioral Healthcare, and foreign governments, including Belgium, Finland, Iceland, Israel, Norway, Switzerland, and the World Health Organization. The author of over 125 scientific publications, he has served on the Boards and Editorial Boards of a number of societies and journals, including ASAM and the International Society of Addiction Medicine (ISAM). He is co-editor of the leading book on treatment matching in the field, The ASAM Patient Placement Criteria for Substance-Related Disorders and editor of Addiction Treatment Matching. In addition to his role at RecoverySearch, Dr. Gastfriend is also Vice President for Scientific Communications at Alkermes, Inc. (NASDAQ: ALKS) where he is involved in research, education and scientific publication on extended-release naltrexone (VIVITROL®) and the company's efforts in the field of addiction treatment.

    Brian Hurley

    MD, MBA, DFASAM

    Dr. Brian Hurley is an addiction psychiatrist and Medical Director for Co-Occurring Disorder Services for the Los Angeles County Department of Mental Health (LACDMH), supporting the identification and management of co-occurring substance use among patients with mental illness served by LACDMH. He is an assistant professor of Addiction Medicine at UCLA. 

    Brian serves as the Treasurer and is a Distinguished Fellow of the American Society of Addiction Medicine. Brian joined ASAM in 2002 as a first year medical student, and has served on the ASAM Board of Directors in various capacities since 2003. Brian previously served as chair of ASAM’s Membership Committee and Physicians-in-Training Committee and is formerly ASAM’s alternate delegate to the American Medical Association. Brian additionally served on the EVP/CEO search committee in 2010 that led to Penny Mill’s selection as ASAM’s current EVP/CEO. He has additional served in various roles for the Massachusetts Society of Addiction Medicine, New York Society of Addiction Medicine, and California Society of Addiction Medicine.

    Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA), and was previously a Veterans Administration National Quality Scholar at the VA Greater Los Angeles Healthcare System. He completed residency training at the Massachusetts General Hospital and McLean Hospital, where he was Chief Resident in Addiction Psychiatry and addiction psychiatry fellowship training at Bellevue Hospital and the New York Veterans Administration. Brian is a graduate of the Keck School of Medicine and Marshall School of Business of the University of Southern California. He was a 2012 American College of Psychiatrists Laughlin fellow, a 2010-2013 American Psychiatric Association (APA) Public Psychiatry Fellow, and a 2015-2017 Group for Advancement of Psychiatry Fellow. Brian has previously served on the Board of Trustees of the APA.

    Eric E. Gastfriend

    MBA

    Eric Gastfriend is the Co-Founder and CEO of DynamiCare Health, a tech startup that is fighting substance addiction with evidence-based motivational tools. Previously, he was General Manager of Happy Cloud, a cloud gaming startup, where he oversaw software development and business development. Happy Cloud raised $7M in venture capital funding to make on-demand gaming possible for customers such as Warner Bros. Eric is currently managing DynamiCare Health’s strategy, operations, and fundraising. He earned his B.A. magna cum laude from Brown University and MBA from Harvard Business School. 

  • Addiction Medicine Fellowships: Training Clinical Experts, Faculty and Change Agents (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    With last year's formal recognition by the American Board of Medical Specialties and the Accreditation Council for Graduate Medical Education, opportunities are rapidly expanding for educational leaders in addiction medicine. This workshop will help participants who are interested in developing the new fellowship training programs that will build the national workforce of expert subspecialists and help integrate addiction medicine across the continuum of medical education. Based on a technical assistance model that has helped establish more than 40 fellowships since 2011, the session with include an exercise in step-by-step fellowship planning that can be used to start a subsequent accreditation application. Interested participants will be linked to ongoing support.

    Addiction medicine took a quantum leap forward in 2016 as the two major organizations overseeing medical specialty training and certification formally recognized the discipline as the nation's newest medical subspecialty. The historic decisions by the American Board of Medical Specialties (ABMS) and the Accreditation Council for Graduate Medical Education (ACGME) have now cleared the way for a dramatic growth in fellowship training programs. At the same time, collaboration between addiction medicine leaders and federal agencies has ignited efforts to integrate the teaching of the latest addiction science and evidence-based practices throughout the medical education continuum. This watershed moment presents a rare opportunity for those willing to assume leadership roles, and this workshop is designed to help them get started. The session will be modeled on the technical assistance program of The Addiction Medicine Foundation's National Center for Physician Training in Addiction Medicine. The strategy recognizes that addiction medicine fellowships are the necessary ingredient for producing an expert workforce of physician specialists, and for assuring that all physicians receive education and training in this essential competency. The starting point for any new fellowship is a champion to lead the effort, and the workshop, therefore, is designed for physicians who share this motivation. Physicians who are already teaching in a medical school or academic medical center are ideally placed, but fellowships may also be launched by community-based physicians whose prior experience with academic medicine is limited. This workshop will provide participants with an understanding of a fellowship program's key components, including personnel and curriculum. Utilizing a case study approach, it will also address areas such as developing the necessary institutional relationships to build a program and finding support to fuel its growth. The session will include an exercise in which participants will team up to complete a worksheet that can serve as the step-by-step blueprint for an actual accreditation application. Throughout the workshop, leaders from TAMF's National Center will interact with participants, drawing upon their experience assisting in the development of more than 40 addiction medicine fellowships since 2011. Ongoing support for interested participants will be arranged at the workshop's conclusion.

    Kevin Kunz

    MD, MPH, DFASAM

    Kevin Kunz, M.D., M.P.H., DFASAM is Executive Vice President of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation. He served as ABAM President from 2008-2011, and previously served as an ASAM Director and Chair of the ASAM Chapters Council. He was Co-chair of the ASAM Medical Specialty Action Group, which recommended that an independent medical board be established to expand the formal involvement of the larger medical community and all of health care in the prevention and treatment of addiction.

    Andrew Danzo

    BA

    Mr. Danzo is Coordinator of the ABAM Foundation National Center for Physician Training in Addiction Medicine. He is also Associate Director of Program Development in the University at Buffalo Primary Care Research Institute and research instructor in the University at Buffalo Department of Family Medicine.

    Lon R. Hays

    MD, MBA, DFAPA, DFASAM

    Lon Roberts Hays, M.D., M.B.A. graduated from medical school at the University of Kentucky in 1982 then pursued residency training at the University of Kentucky, which he completed in 1986. At that time he joined the faculty in the Department of Psychiatry where he has served as Chair from 1998 to 2018, and is director of the Addiction Medicine Fellowship.  In addition to being Board Certified by the American Board of Psychiatry and Neurology, Dr. Hays also is certified by the American Board of Addiction Medicine and has Added Qualifications in both Addiction Psychiatry and Geriatric Psychiatry. He completed a Certificate of Medical Management in 1998 and went on to obtain his M.B.A. from the University of Kentucky Gatton School of Business in May 2001.  Dr. Hays is a Co-investigator on numerous grants involving drugs of abuse.  He is the Director of Area V of the American Academy of Addiction Psychiatry, President of the Addiction MedicineFoundation, a Distinguished Fellow of the American Psychiatric Association, and an elected member and Fellow of the American College of Psychiatrists."

    Alexander Y. Walley

    MD, MSc, FASAM

    Alexander Y. Walley, M.D., M.Sc., is an Associate Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Addiction Medicine Fellowship program and founded the Inpatient Addiction Consult Service at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients and methadone maintenance treatment. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. 

    Jeanette M. Tetrault

    MD, FACP, FASAM

    Dr. Tetrault’s scholarly work focuses on care of patients with addicition and the medical co-morbidities associated with substance use, mainly HIV and Hepatitis C. She is a diplomate of the American Board of Addiction Medicine. Dr. Tetrault is a physician providing primary care and buprenorphine/naloxone treatment at the Central Medical Unit of the APT Foundation, a multi-specialty addiction treatment facility, and is an attending physician at Yale New Haven Hospital (YNHH). She is the co-director of the Addiction Recovery Clinic in the Adult Primary Care Clinic at the St. Raphael's Campus of YNHH, which serves both a clinical care and a teaching mission. She was selected as a Macy Foundation Faculty Scholar in 2017. She is the Program Director for the Yale Addiction Medicine Fellowship Program and serves on the Board of Directors for The Addiction Medicine Foundation and the Addiction Medicine Fellowship Directors Association. She is a past-president of the New England Region of SGIM and co-chair of the Alcohol, Tobacco and Other Drug Use Interest Group for SGIM.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Navigating Payment Pathways Part 2

    Contains 3 Component(s), Includes Credits

    This free CME webinar series is designed to prepare physicians and their billing staff for the basics of modern healthcare payment models and methods of incorporating these models into addiction treatment practice. Presented by a healthcare reimbursement expert, viewers will learn the language used by health payers to improve understanding of billing and coding techniques. Some tips about determining patient coverage for services, handling prior authorization requests, and submitting claims to payers will be included. The first in the series created to examine some of the basic and advanced issues that many may face when working with insurance companies and other health payers. The second webinar will be held on March 7th, and the third session will be a panel discussion held at the Annual Conference with ASAM members employed by health insurers.

    This free CME webinar series is designed to prepare physicians and their billing staff for the basics of modern healthcare payment models and methods of incorporating these models into addiction treatment practice. Presented by a healthcare reimbursement expert, viewers will learn the language used by health payers to improve understanding of billing and coding techniques. Some tips about determining patient coverage for services, handling prior authorization requests, and submitting claims to payers will be included.

    The first in the series created to examine some of the basic and advanced issues that many may face when working with insurance companies and other health payers. The second webinar will be held on March 7th, and the third session will be a panel discussion held at the Annual Conference with ASAM members employed by health insurers.


    This webinar is primarily intended for addiction medicine specialists; medical office billing staff; opioid treatment program providers; DATA-waived providers

    At the conclusion of the webinar, participants should be able to:

    • Recognize health care reimbursement models and common terms used by most health care payers
    • Explain how health care payers make coverage decisions and discuss how that relates to their practice
    • Explain recent or upcoming policy changes and identify implications or areas for provider involvement
    • Assess the importance of utilization management requests, appeals, and compliance protections to make informed decisions in their practice
    • Synthesize information to assist patients and staff with coverage questions and appeals
    • Evaluate billing best practices to appropriately bill for tasks performed in basic or advanced situations
    • Create a set of resources/list of best practices that can be used to support the participant's practice
    • Analyze information about payers/reimbursement models to develop a plan for personal engagement with payer to positively impact their practice.

    ACCME Accreditation Statement
    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

     AMA Credit Designation Statement:
    The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA
    PRA Category 1 Credits™
    .
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    CME Committee

    Name

    Disclosure Information

    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair

    None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None

    Noel Ilogu, MD, MRCP

    None

    Herbert L. Malinoff, MD, FACP, FASAM

    Nonr

    Edwin A. Salsitz, MD, FASAM, Reviewer

    Reckitt-Benckiser: Honorarium, Speaker

     

    John C. Tanner, DO, FASAM, CCFC, MRO

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Disclosure Information

    Gordon Schatz, JD

    Quorum: Consulting (No services or products consumed by or used on patients) Honorarium, Speaker

    Dr. George Kolodner, MD, DLFAPA, FASAM

    None

    Frank James, MD, JD, FASAM, FACLM

    Optum: Honorarium, Speaker

    Anne Fernandez, MD

    None

    Faculty

    Disclosure Information

    Gordon Schatz, JD

    Quorum: Consulting (No services or products consumed by or used on patients) Honorarium, Speaker


  • Navigating Payment Pathways Part 1

    Contains 3 Component(s), Includes Credits

    This free CME webinar series is designed to prepare physicians and their billing staff for the basics of modern healthcare payment models and methods of incorporating these models into addiction treatment practice. Presented by a healthcare reimbursement expert, viewers will learn the language used by health payers to improve understanding of billing and coding techniques. Some tips about determining patient coverage for services, handling prior authorization requests, and submitting claims to payers will be included. The first in the series created to examine some of the basic and advanced issues that many may face when working with insurance companies and other health payers. The second webinar will be held on March 7th, and the third session will be a panel discussion held at the Annual Conference with ASAM members employed by health insurers.

    This free CME webinar series is designed to prepare physicians and their billing staff for the basics of modern healthcare payment models and methods of incorporating these models into addiction treatment practice. Presented by a healthcare reimbursement expert, viewers will learn the language used by health payers to improve understanding of billing and coding techniques. Some tips about determining patient coverage for services, handling prior authorization requests, and submitting claims to payers will be included.

    The first in the series created to examine some of the basic and advanced issues that many may face when working with insurance companies and other health payers. The second webinar will be held on March 7th, and the third session will be a panel discussion held at the Annual Conference with ASAM members employed by health insurers.


    This webinar is primarily intended for addiction medicine specialists; medical office billing staff; opioid treatment program providers; DATA-waived providers

    At the conclusion of the webinar, participants should be able to:

    • Recognize health care reimbursement models and common terms used by most health care payers
    • Explain how health care payers make coverage decisions and discuss how that relates to their practice
    • Explain recent or upcoming policy changes and identify implications or areas for provider involvement
    • Assess the importance of utilization management requests, appeals, and compliance protections to make informed decisions in their practice
    • Synthesize information to assist patients and staff with coverage questions and appeals
    • Evaluate billing best practices to appropriately bill for tasks performed in basic or advanced situations
    • Create a set of resources/list of best practices that can be used to support the participant's practice
    • Analyze information about payers/reimbursement models to develop a plan for personal engagement with payer to positively impact their practice.

    ACCME Accreditation Statement
    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

     AMA Credit Designation Statement:
    The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA
    PRA Category 1 Credits™
    .
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    CME Committee

    Name

    Disclosure Information

    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair

    None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None

    Noel Ilogu, MD, MRCP

    None

    Herbert L. Malinoff, MD, FACP, FASAM

    Nonr

    Edwin A. Salsitz, MD, FASAM, Reviewer

    Reckitt-Benckiser: Honorarium, Speaker

     

    John C. Tanner, DO, FASAM, CCFC, MRO

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Disclosure Information

    Gordon Schatz, JD

    Quorum: Consulting (No services or products consumed by or used on patients) Honorarium, Speaker

    Dr. George Kolodner, MD, DLFAPA, FASAM

    None

    Frank James, MD, JD, FASAM, FACLM

    Optum: Honorarium, Speaker

    Anne Fernandez, MD

    None

    Faculty

    Disclosure Information

    Gordon Schatz, JD

    Quorum: Consulting (No services or products consumed by or used on patients) Honorarium, Speaker


    Gordon Schatz JD

    Gordon Schatz JD, President of Schatz Reimbursement Strategies LLC,
    represents medical innovators, health care professionals, and manufacturers of
    medical devices, drugs, and diagnostics on coding, coverage and payment. He has
    worked with ASAM on coding issues. Over the past 25 years, he has improved billing
    and reimbursement policies for innovative health care services/products by
    CMS/Medicare, other government and private payers, at the national and local levels.

  • NP/PA 24-Hour Waiver Training - AANP

    Contains 2 Product(s)

    Free 24-hour CE education for nurse practitioners seeking to qualify for a waiver to prescribe buprenorphine in an office-based treatment setting.

    image

    ASAM, AANP and AAPA have formed a collaborative to provide the 24-hour waiver training for nurse practitioners and physician assistants. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    To qualify to prescribe medications for Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe Schedule III, IV, or V medications for pain
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    **The content was originally developed for the 8-hour DATA2000 training for physicians. This content is now offered to NPs/PAs and appropriate provider language will be changed as content continues to evolve.

    This training is presented in two parts. Part I is the 8-hour training for physicians, NPs and PAs. Part II is the additional 16 hours for NPs/PAs required by CARA. In Part II, you will see the topics listed in CARA with specific content under those topics.

    Before you begin and to receive AANP CE Credit, you must register through the AANP CE Center. Click here to register. 

    Once registration is complete on the AANP CE Center, return to the ASAM e-Learning Center to begin and/or continue the content.

    The collaborative of ASAM, AANP and AAPA identified and reviewed this content to provide the NP/PA training required by CARA.

    The NP/PA 24-Hour Waiver Training is available for free through 2018 in part by an unrestricted educational grant from Indivior.

    The 16-hour product developed includes all additional education required by the Comprehensive Addiction and Recovery Act (CARA) for nurse practitioners to successfully apply for a waiver to prescribe buprenorphine for office-based treatment of opioid use disorders.

    This activity is approved for 24.0 contact hour(s) of continuing education (which includes 18.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 16122474. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider or through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician (physician must be waivered) to prescribe medications for the treatment of OUD may be required.
    •   

    Download this helpful FAQ for technical issues.